All news

Cerenome posts first CNSide revenue, secures $20 million facility

Alpha Vantage · Mugglehead Investment Magazine · · AI-summarised by FinFlash

Cerenome reported US$0.7 million in CNSide diagnostic revenue for Q3 2026 alongside an US$8.7 million net loss. The company secured a US$20 million financing facility carrying interest, royalties and conversion rights to fund commercial scale-up and development. Further funding depends on mid-2027 cancer trial readouts, with Medicare reimbursement expected in early 2027.

Read original source

CNSY company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.